Zentalis Pharmaceuticals Advances Ovarian Cancer Drug with Accelerated Approval Pathway Intact — Zentalis Pharmaceuticals, Inc.

Event summary

Zentalis completed enrollment in DENALI Part 2a and 2b trials for azenosertib, with Part 2c currently enrolling.
FDA had no objection to the selected dose of azenosertib (400mg QD 5:2) in Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
$174.6 million in cash as of June 30, 2026, providing runway into late 2027.
Topline readout from DENALI Part 2 expected in 1H 2027 to support accelerated approval pathway.

The big picture

Zentalis Pharmaceuticals is advancing its investigational WEE1 inhibitor, azenosertib, as a biomarker-driven treatment for ovarian cancer. The company's strategic focus on the Cyclin E1-positive PROC population aligns with broader industry trends toward personalized medicine and targeted therapies. With $174.6 million in cash providing runway into late 2027, Zentalis aims to bring a potential first-in-class therapy to market for an underserved patient population.

What we're watching

Regulatory Strategy: Whether the FDA's acknowledgment of DENALI Part 2 study population will support accelerated approval.
Clinical Data Maturation: The pace at which topline readout from DENALI Part 2 in 1H 2027 will influence regulatory decisions.
Commercial Expansion: How Zentalis plans to leverage azenosertib's potential in platinum-sensitive settings and additional tumor types.